Rachel Wiser Runs NYC Half-Marathon for LRA in Honor of Her Childhood Friend
Rachel Wiser is running the United Airlines NYC Half marathon with the Lupus Research Alliance (LRA) Team Life Without...
New York, NY– March 1. The Lupus Research Alliance and clinical affiliate, Lupus Therapeutics will partner with Takeda Pharmaceutical Company Limited to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916). TAK-079 is a fully human monoclonal antibody, meaning that it is produced in the laboratory using human DNA sequences.
The study will be offered in 20 research centers throughout the country, many of which are part of the Lupus Clinical Investigators Network (LuCIN) that Lupus Therapeutics oversees.
The full press release is available on the Lupus Therapeutics website.